Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials von Basu, B., Vitfell-Pedersen, J., Moreno Garcia, V., Puglisi, M., Tjokrowidjaja, A., Shah, K., Malvankar, S., Anghan, B., de Bono, J.S., Kaye, S.B., Molife, L.R., Banerji, U.

Volltext

Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1? von Postel-Vinay, S., Gomez-Roca, C. A., Molife, L. R., Anghan, B., Soria, J., Kaye, S. B., Paoletti, X.

Volltext

Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit von Ang, J. E., Olmos, D., Moreno Garcia, V., Brunetto, A., Papadatos-Pastos, D., Arkenau, H., Blanco, M., Baird, R. D., Cassier, P. A., Tan, D. S. W., Kristeleit, R. S., Dolly, S., Shah, K. J., Amin, B., Anghan, B. G., Molife, L. R., Banerji, U., De Bono, J. S., Kaye, S. B.

Volltext